Effect of Probiotics in Non-alcoholic Fatty Liver Disease and Steatohepatitis

Cirrhosis, Liver Clinical Trial

— PRONE  

Official title:

Effect of Probiotics in Non-Alcoholic Fatty Liver Disease and Steatohepatitis Measured by Transient Elastography (PRONE Study).

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04175392
• Other study ID #: 2019-129
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: January 12, 2021
• Est. completion date: March 1, 2022

Study information

• Verified date: August 2022
• Source: William Beaumont Hospitals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the effect of probiotics, a beneficial intestinal bacteria supplement, if it will cause improvement of the non-alcoholic fatty liver disease (NAFLD) and or non-alcoholic steatohepatitis (NASH- an inflammation with concurrent fatty accumulation of the liver) as measured by transient elastography - an ultrasound of the liver that assess the elastic properties (density) and stiffness of the liver tissue. This study will enroll patients 18 years and older with diagnosis of NAFLD and or NASH.

Description:

Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) are conditions without symptoms where inflammation in the liver can progress to end-stage liver disease (cirrhosis). Current standard of care for these conditions include control of metabolic syndrome which includes but is not limited to a patient's high blood pressure (hypertension), high cholesterol (hyperlipidemia), high blood sugar (hyperglycemia) and excess fat around the waist (central obesity and waist circumference) with lifestyle modifications including diet, exercise and medications. While the mechanism for inflammation on the liver in NAFLD and NASH is not completely understood, the American Association for the Study of Liver Diseases currently suspects it may be connected with the metabolism in the bowel and subsequent hepatic (liver) circulation. The bacteria of the intestines (microbiome or gut flora) may play a role in the inflammatory cascade through the bloodstream that affects the liver.

The World Health Organization (WHO) and the Food and Agricultural Organization (FAO) of the United Nations define Probiotics as a "live microorganism" which, when taken in adequate amounts confer a health benefit in the gastrointestinal tract. This study will be done to determine if probiotic use may be a viable treatment option for NAFLD and NASH and to establish a link that the intestinal microbiome or gut flora plays a role in liver inflammation which will be measured by elastography.

Patients with NAFLD and NASH seen in office consultation of the investigator will be approached to participate in the randomized like a flip of a coin, double-blind (patients and researchers will be blinded), placebo controlled study. Participant will be counseled on diet and exercise. The participants will receive information on a standardized Mediterranean diet based nutrition program as well as direction for recommended 30 minutes of aerobic exercise 3 times weekly. A baseline transient elastography, blood test such as liver enzymes Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) will be drawn, including hemoglobin A1C (diabetic marker), cholesterol in the form of Low-Density Lipoprotein (LDL/bad cholesterol) and assessment of Body Mass Index (BMI).

Participants will be randomized by pharmacy into 2 groups, a control group and a treatment group. The treatment group will be provided with a 6 month supply of Align probiotic once daily supplementation; the control group will be given a placebo for 6 months along with both groups given instructions on how to take the supplement. Subjects will receive a 1 month phone call follow up to ensure adherence to study instructions and daily oral intake of supplement, and again at 3 months. Study participation will end at 6 months after the repeat of liver enzymes, hemoglobin A1C, lipid panel, assessment of BMI and transient elastography as completed at scheduled clinical appointment.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 14
• Est. completion date: March 1, 2022
• Est. primary completion date: March 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of NAFLD and/or NASH

• Subject aged 18 and older

• Non-pregnant - Self-reported

• Subject with decision making capacity to understand and consent to study procedures

• Ability to follow study related activities regarding medications, diet and exercise

Exclusion Criteria:

• Without diagnosis of NAFLD or NASH

• History of liver disease from other causes, including but not limited to hepatitis, autoimmune, alcohol use, fatty liver of pregnancy, Wilson's disease, primary or secondary hemochromatosis

• Patients aged less than 18 years

• Self-reported pregnant patients

• Inability to understand, follow and consent to study procedures

• Hepatic decompensation defined as gastrointestinal bleeding, ascites, hepatic encephalopathy

• Inability to engage in exercise

• Currently immunocompromised or taking immunosuppressive drugs

• Milk protein allergy

• Recent or active chemotherapy for malignancy

• Gastrointestinal malignancy

• Gastrointestinal disease such as Ulcerative Colitis, Crohn's Disease as these alter the microbiome

• Recent antibiotic therapy (within 6 months)

• Known allergy to probiotics

• History of major gastrointestinal surgery such as resection of the colon

• No concomitant use of probiotic from any source (i.e., kefir, certain yogurts, live culture, sauerkraut)

• Liver scan >2 months prior to enrollment

• Weight loss >5 pounds in the last 2 months

• Any implanted battery operated device (i.e. AICD, pacemaker, loop recorder, cochlear implant)

Related Conditions & MeSH terms

• Cirrhosis, Liver
• Fatty Liver
• Fatty Liver Disease
• Fibrosis
• Fibrosis, Liver
• Liver Cirrhosis
• Liver Diseases
• Non-alcoholic Fatty Liver Disease
• Steatohepatitis, Nonalcoholic

Intervention

Drug:
• Align Probiotic Supplement Capsule
Align Probiotic 1 billion units, 1 capsule once daily
• Placebos
Placebos capsule 1 capsule Once daily

Locations

Country	Name	City	State
United States	Beaumont Hospital	Farmington Hills	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
William Beaumont Hospitals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Probiotic Effects on Liver Fibrosis	Probiotic effects on liver fibrosis as measured by transient elastography, as a change from baseline to 6 months, measured on a scale from 1-4. 1= a clinical grade of F0-F1 and represents 2-7 kilopascals in elastography testing. 4= a clinical grade of F4 and represents 14 kilopascals or higher in elastography testing. A higher score on the scale represents worsening liver scarring. Positive numbers indicate an increase in fibrosis; negative numbers indicate decrease in fibrosis.	6 months
Secondary	Probiotic Effects on Liver Enzymes, AST	Probiotic effects on Liver enzymes, AST as a change from baseline to 6 months, measured in units per liter. Positive numbers indicate an increase in AST; negative numbers indicate decrease in AST	6 months
Secondary	Probiotic Effects on Liver Enzymes, ALT	Probiotic effects on Liver enzymes, ALT as a change from baseline to 6 months, measured in units per liter. Positive numbers indicate an increase in ALT; negative numbers indicate decrease in ALT	6 months
Secondary	Probiotic Effects on Diabetic Markers	Probiotic effects on Diabetic Markers as measured by hemoglobin A1C blood test as a change from baseline to 6 months, measured in percent. Positive numbers indicate an increase in hemoglobin A1c; negative numbers indicate decrease in hemoglobin A1c	6 months
Secondary	Probiotic Effects on BMI	Probiotic effects on Body Mass Index (BMI) wherein weight and height will be combined to report BMI in kg/m^2 as a change from baseline to 6 months. Positive numbers indicate an increase in BMI; negative numbers indicate decrease in BMI.	6 months
Secondary	Probiotic Effects on LDL	Probiotic effects on Low-density Lipoprotein (LDL) as a change from baseline to 6 months, measured in milligrams per deciliter. Positive numbers indicate an increase in LDL; negative numbers indicate decrease in LDL	6 months